Recent News from Incyte, Merck and Nektar

Incyte's FDA Approval
Based on encouraging data from the REACH1 trial the FDA approved a label expansion of the Incyte (INCYproduct Jakafi (ruxolitinib) for graft-versus-host disease (GVHD) in people 12 years and older.

The FDA previously granted Jakafi Breakthrough therapy designation and orphan drug status for acute GVHD.

GVHD is a condition that might occur after an . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.